NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
Clinical Trials
12 trialsNCT01487174 2022-05-13
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Kadmon Corporation, LLC
Phase 3 Terminated
NCT01244191 2021-04-06
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Daiichi Sankyo
Phase 3 Terminated
NCT02893332 2021-02-03
Sindas
Sichuan Provincial People's Hospital
Phase 3 Terminated
NCT02775006 2019-04-30
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
The Netherlands Cancer Institute
Phase 3 Terminated
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT02178397 2017-07-17
FLARE
Centre Francois Baclesse
Phase 3 Terminated
NCT01377376 2016-12-07
ATTENTION
Kyowa Kirin Co., Ltd.
Phase 3 Terminated
NCT00412217 2016-11-25
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT00738881 2015-10-29
MARVEL
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated